Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
|Articles|March 8, 2010
- September 2009
- Volume 3
- Issue 9
IASLC's 13th World Conference on Lung Cancer
Author(s)Onclive Team
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, improving patient outcomes.
- Targeted therapies and immunotherapies offer more effective, less invasive options compared to traditional methods.
Advertisement
Articles in this issue
over 16 years ago
Studies from Around the Globeover 16 years ago
By the Numbers: If the US Health Care System Had Only 100 Physiciansover 16 years ago
In the News BriefsAdvertisement
Related to this article
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5